GLP-1 analogues

Nauck MA, Hompesch M, Fihpczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2006 114 417 23. 

Alternatively, the patient may be prescribed a combination of conventional OADs and a DPP IV inhibitor or a GLP-1 analogue... 

Prolongation of the 2-min half-life of native human GLP-1 was achieved through a rational analysis of the structure-activity relationship of numerous fatty acid-derivatized human GLP-1 analogues that showed resistance to DPPIV-mediated inactivation and avoided renal clearance through binding to albumin that exceeds the molecular threshold for glomerular filtration [11]. 

Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol 2009 68 898-905. 

Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue liraglutide. Br J Pharmacol 2010 70 807-14. 

Liraglutide is a GLP-1 analogue, administered subcutaneously once a day as an isotonic solution. It has a substitution of lysine to arginine at position 34 and attachment of a C16 fatty acid at position 26. The fmax and half-life are both about 12 hours. Steady state occurs at about 4 days [59, 60 ]. 

Russell-Jones D. Molecular pharmacological and clinical aspects of liraglutide a once daily human GLP-1 analogue. Mol CeU Endocrinol 2009 297 137-40. 

---